68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
36
DOTATATE tracer PET scan for meningioma
BC Cancer - Vancouver
Vancouver, British Columbia, Canada
Target radiation volume
The volume of gross total volume (GTV), clinical target volume (CTV), planned target volume (PTV) contours, and volume of dose exposure to normal brain tissue using standard imaging and DOTATE-PET scan
Time frame: 2 years
Local control
Time frame: 2 years
Progression-free survival
Time frame: 2 years
Perceived usefulness by radiation oncologist
Time frame: 2 years
Adverse event
Time frame: 2 years
Rate of DOTATATE-scan completion
Time frame: 2 years
Extent of post-operative disease volume compared to MRI
Time frame: 2 years
Overall survival
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.